Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 175

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies

Open access
Wang, Chunyan, van Haperen, Rien, Gutiérrez-Álvarez, Javier, Li, Wentao, Okba, Nisreen M. A., Albulescu, Irina, Widjaja, Ivy, van Dieren, Brenda, Fernandez-Delgado, Raul, Sola, Isabel, Hurdiss, Daniel L., Daramola, Olalekan, Grosveld, Frank, van Kuppeveld, Frank J. M., Haagmans, Bart L., Enjuanes, Luis, Drabek, Dubravka, Bosch, Berend-Jan·2021·Nature Communications

Abstract

The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell entry and the focus for development of protective antibodies and vaccines. Structural studies show exposed sites on the spike trimer that might be targeted by antibodies with cross-species specificity. Here we isolated two human monoclonal antibodies from immunized humanized mice that display a remarkable cross-reactivity against distinct spike proteins of betacoronaviruses including SARS-CoV, SARS-CoV-2, MERS-CoV and the endemic human coronavirus HCoV-OC43. Both cross-reactive antibodies target the stem helix in the spike S2 fusion subunit which, in the prefusion conformation of trimeric spike, forms a surface exposed membrane-proximal helical bundle. Both antibodies block MERS-CoV infection in cells and provide protection to mice from lethal MERS-CoV challenge in prophylactic and/or therapeutic models. Our work highlights an immunogenic and vulnerable site on the betacoronavirus spike protein enabling elicitation of antibodies with unusual binding breadth.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-21968-w

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 62

  1. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020). · DOI · Paper page
  2. Gorbalenya, A. et al. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020, 03–04 (2020).
  3. Peiris, J., Guan, Y. & Yuen, K. Severe acute respiratory syndrome. Nat. Med. 10, S88–S97 (2004). · DOI · Paper page
  4. Gaunt, E. R., Hardie, A., Claas, E. C., Simmonds, P. & Templeton, K. E. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J. Clin. Microbiol. 48, 2940–2947 (2010). · DOI · Paper page
  5. Lim, Y. X., Ng, Y. L., Tam, J. P. & Liu, D. X. Human coronaviruses: a review of virus–host interactions. Diseases 4, 26 (2016). · DOI · Paper page
  6. Walsh, E. E., Shin, J. H. & Falsey, A. R. Clinical impact of human coronaviruses 229E and OC43 infection in diverse adult populations. J. Infect. Dis. 208, 1634–1642 (2013). · DOI · Paper page
  7. Morfopoulou, S. et al. Human coronavirus OC43 associated with fatal encephalitis. N. Engl. J. Med. 375, 497–498 (2016). · DOI · Paper page
  8. Su, S. et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 24, 490–502 (2016). · DOI · Paper page
  9. Chan, J. F., To, K. K., Tse, H., Jin, D. & Yuen, K. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol. 21, 544–555 (2013). · DOI · Paper page
  10. Hu, B., Ge, X., Wang, L. & Shi, Z. Bat origin of human coronaviruses. Virol. J. 12, 1–10 (2015). · DOI · Paper page
  11. Burton, D. R. & Walker, L. M. Rational vaccine design in the time of COVID-19. Cell Host Micro. 27, 695–698 (2020). · DOI
  12. Burton, D. R., Poignard, P., Stanfield, R. L. & Wilson, I. A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337, 183–186 (2012). · DOI · Paper page
  13. Pappas, L. et al. Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature 516, 418–422 (2014). · DOI · Paper page
  14. Chen, Y. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173, 417–429.e10 (2018). · DOI · Paper page
  15. Flyak, A. I. et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell 164, 392–405 (2016). · DOI · Paper page
  16. Wec, A. Z. et al. Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses. Cell 169, 878–890.e15 (2017). · DOI · Paper page
  17. Gilchuk, P. et al. Multifunctional pan-ebolavirus antibody recognizes a site of broad vulnerability on the ebolavirus glycoprotein. Immunity 49, 363–374 (2018). e10. · DOI
  18. Chan, K. et al. Cross-reactive antibodies in convalescent SARS patients’ sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J. Infect. 67, 130–140 (2013). · DOI · Paper page
  19. Wec, A. Z. et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 369, 731–736 (2020). · DOI · Paper page
  20. Kirchdoerfer, R. N. et al. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci. Rep. 8, 1–11 (2018).
  21. Li, Z. et al. The human coronavirus HCoV-229E S-protein structure and receptor binding. Elife 8, e51230 (2019). · DOI · Paper page
  22. Shang, J. et al. Cryo-EM structure of infectious bronchitis coronavirus spike protein reveals structural and functional evolution of coronavirus spike proteins. PLoS Pathog. 14, e1007009 (2018). · DOI
  23. Shang, J. et al. Cryo-Electron Microscopy Structure of Porcine Deltacoronavirus Spike Protein in the Prefusion State. J. Virol. https://doi.org/10.1128/JVI.01556-17 (2018). · DOI
  24. Tortorici, M. A. et al. Structural basis for human coronavirus attachment to sialic acid receptors. Nat. Struct. Mol. Biol. 26, 481–489 (2019). · DOI · Paper page
  25. Walls, A. C. et al. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 531, 114–117 (2016). · DOI · Paper page
  26. Yuan, Y. et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat. Commun. 8, 1–9 (2017). · DOI · Paper page
  27. Menachery, V. D. et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21, 1508–1513 (2015). · DOI · Paper page
  28. Wang, C. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 11, 1–6 (2020). · DOI · Paper page
  29. Lv, H. et al. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Rep. 31, 107725 (2020). · DOI · Paper page
  30. Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020). · DOI · Paper page
  31. Lv, Z. et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science 369, 1505–1509 (2020). · DOI · Paper page
  32. Haagmans, B. L. et al. SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model. Preprint at https://doi.org/10.1101/2020.08.24.264630 (2020). · DOI
  33. Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e6 (2020). · doi:10.1016/j.cell.2020.02.058 · Paper page
  34. Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 217, e20201181 (2020). · DOI · Paper page
  35. Lang, S. et al. Antibody 27F3 broadly targets influenza A group 1 and 2 hemagglutinins through a further variation in VH1-69 antibody orientation on the HA stem. Cell Rep. 20, 2935–2943 (2017). · DOI
  36. Chen, F., Tzarum, N., Wilson, I. A. & Law, M. VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design. Curr. Opin. Virol. 34, 149–159 (2019). · DOI
  37. Avnir, Y. et al. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. PLoS Pathog. 10, e1004103 (2014). · DOI
  38. Gorny, M. K. et al. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Mol. Immunol. 46, 917–926 (2009). · DOI
  39. Williams, W. B. et al. HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science 349, aab1253 (2015). · DOI · Paper page
  40. Joyce, M. G. et al. Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses. Cell 166, 609–623 (2016). · DOI · Paper page
  41. Walls, A. C. et al. Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat. Struct. Mol. Biol. 23, 899 (2016). · DOI · Paper page
  42. Walls, A. C. et al. Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc. Natl Acad. Sci. USA 114, 11157–11162 (2017). · DOI · Paper page
  43. Ekiert, D. C. et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489, 526–532 (2012). · DOI · Paper page
  44. Schmidt, A. G. et al. Viral receptor-binding site antibodies with diverse germline origins. Cell 161, 1026–1034 (2015). · DOI · Paper page
  45. Routledge, E., Stauber, R., Pfleiderer, M. & Siddell, S. G. Analysis of murine coronavirus surface glycoprotein functions by using monoclonal antibodies. J. Virol. 65, 254–262 (1991). · DOI
  46. Elshabrawy, H. A., Coughlin, M. M., Baker, S. C. & Prabhakar, B. S. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS ONE 7, e50366 (2012). · DOI · Paper page
  47. Lip, K. M. et al. Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus. J. Virol. 80, 941–950 (2006). · DOI
  48. Supekar, V. M. et al. Structure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein. Proc. Natl Acad. Sci. USA 101, 17958–17963 (2004). · DOI
  49. Xu, Y. et al. Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core. J. Biol. Chem. 279, 30514–30522 (2004). · DOI
  50. King, L. B. et al. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk. Nat. Commun. 10, 1–8 (2019). · DOI
  51. Berger, C. et al. Antigen recognition by conformational selection. FEBS Lett. 450, 149–153 (1999). · DOI
  52. Rappazzo, C. G. et al. An engineered antibody with broad protective efficacy in murine models of SARS and COVID-19. Preprint at https://doi.org/10.1101/2020.11.17.385500 (2020). · DOI
  53. Li, Y. et al. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cell Mol. Immunol. 17, 1095–1097 (2020). · DOI · Paper page
  54. Ladner, J. T. et al. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell Rep. Med. 2, 100189 (2021). · DOI · Paper page
  55. Xu, K. et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat. Med. 24, 857–867 (2018). · DOI · Paper page
  56. Nachbagauer, R. & Krammer, F. Universal influenza virus vaccines and therapeutic antibodies. Clin. Microbiol. Infec. 23, 222–228 (2017). · DOI · Paper page
  57. Crowe, J. E. Jr Principles of broad and potent antiviral human antibodies: insights for vaccine design. Cell Host Micro. 22, 193–206 (2017). · DOI
  58. Gahn, T. A. & Sugden, B. An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene. J. Virol. 69, 2633–2636 (1995). · DOI · Paper page
  59. Liu, H. F., Ma, J., Winter, C. & Bayer, R. Recovery and Purification Process Development for Monoclonal Antibody Production (MAbs Ser. 2, Taylor & Francis, 2010). · DOI · Paper page
  60. Hulswit, R. J. G. et al. Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. Proc. Natl Acad. Sci. USA 116, 2681–2690 (2019). · DOI · Paper page
  61. Raj, V. S. et al. Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection. Sci. Adv. 4, eaas9667 (2018). · DOI
  62. Okba, N. M. et al. Severe acute respiratory syndrome coronavirus 2− specific antibody responses in coronavirus disease patients. Emerg. Infect. Dis. 26, 1478–1488 (2020). · DOI · Paper page

Cited by

See all 175

Metadata

Authors
Wang, C., van Haperen, R., Gutiérrez-Álvarez, J., Li, W., Okba, N. M. A., Albulescu, I., Widjaja, I., van Dieren, B., Fernandez-Delgado, R., Sola, I., Hurdiss, D. L., Daramola, O., Grosveld, F., van Kuppeveld, F. J. M., Haagmans, B. L., Enjuanes, L., Drabek, D., & Bosch, B.-J.
Venue
Nature Communications
Published
2021-03-17
Volume
12
Issue
1
Pages
1715-1715
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3136693147
Cited by
175
References
15
FWCI
10.51
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. https://app.cochat.ai/papers/10.1038/s41467-021-21968-w
The paper
Wang, C., van Haperen, R., Gutiérrez-Álvarez, J., Li, W., Okba, N. M. A., Albulescu, I., Widjaja, I., van Dieren, B., Fernandez-Delgado, R., Sola, I., Hurdiss, D. L., Daramola, O., Grosveld, F., van Kuppeveld, F. J. M., Haagmans, B. L., Enjuanes, L., Drabek, D., & Bosch, B.-J. (2021). A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. Nature Communications. https://doi.org/10.1038/s41467-021-21968-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.